{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:14:38Z","timestamp":1794539678339,"version":"4.9.1"},"reference-count":34,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,14]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Follicular lymphoma with progression of disease within 24 months (POD24) is associated with poor prognosis and represents clinical challenges. Therefore, we performed a systematic review and pooled analysis of patients with POD24. Twenty-one trials involving 1242 participants were included, assessing the overall response rate (ORR), complete response (CR), duration of response, and progression-free survival. In some trials, we compared pooled response rates between POD24 and non-POD24 populations with the same treatment regimen. Four trials evaluated chimeric antigen receptor (CAR) T-cell therapy in patients with POD24. Pooled analysis showed an ORR of 91.2% (95% confidence interval [CI], 83.7-98.7) with significant heterogeneity (P = .0414; I2 = 68.61%) and a CR of 75.7% (95% CI, 55.1-96.4) with significant heterogeneity (P&amp;lt; .0001; I2 = 93.99%). The specific response rates for different bispecific antibodies in POD24 were pooled analysis, the ORR was 81.6% (95% CI, 75.9-87.3) with no heterogeneity (P = .6958; I2 = 0%), and the CR was 65.7% (95% CI, 57.1-74.3) with moderate heterogeneity (P = .2148; I2 = 34.99%). For anti-CD19 antibody-drug conjugates (ADCs)\/monoclonal antibodies (mAbs), the ORR and CR rate for loncastuximab plus rituximab and tafasitamab plus R2 (lenalidomide + rituximab) were 100% and 79.3%, and 87.5% and 43.2%, respectively. Phosphatidylinositol 3-kinase inhibitors and anti-CD20 mAb-containing regimens were also analyzed in pooled analyses. Our results demonstrated that anti-CD19 CAR T-cell therapy achieved the highest CR rate. Additionally, bispecific antibodies, anti-CD19 ADCs\/mAbs, and the combination of lenalidomide with obinutuzumab or rituximab also exhibited excellent efficacy. Notably, lenalidomide plus obinutuzumab showed superior efficacy compared with R2.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018474","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T21:37:53Z","timestamp":1769463473000},"page":"2495-2505","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Treatment and survival outcomes for patients with follicular lymphoma and POD24: a systematic review and meta-analysis"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0207-2185","authenticated-orcid":false,"given":"Jing","family":"Shen","sequence":"first","affiliation":[{"name":"1Department of Hematology, Capital Medical University Affiliated Beijing Friendship Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4950-4106","authenticated-orcid":false,"given":"Jingyi","family":"Zhang","sequence":"additional","affiliation":[{"name":"2Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7102-9909","authenticated-orcid":false,"given":"Zhengyu","family":"Zhu","sequence":"additional","affiliation":[{"name":"2Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0210-2337","authenticated-orcid":false,"given":"Haobo","family":"Ma","sequence":"additional","affiliation":[{"name":"3Academy of Electronic Warfare, National University of Defense Technology, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3488-3403","authenticated-orcid":false,"given":"Junpeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"4The 961st Hospital of the Joint Logistics Support Force of the People\u2019s Liberation Army, Qiqihar, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7557-4637","authenticated-orcid":false,"given":"Fan","family":"Zhou","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Northern Theater General Hospital, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7312-0832","authenticated-orcid":false,"given":"Hua","family":"Tian","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Northern Theater General Hospital, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8130-2374","authenticated-orcid":false,"given":"JingHua","family":"Liu","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Northern Theater General Hospital, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"issue":"23","key":"2026041408031718200_bib1","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026041408031718200_bib2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/cam4.1918","article-title":"The prognostic significance of PFS24 in follicular lymphoma following first line immunotherapy: a combined analysis of 3 CALGB trials","volume":"8","author":"Lansigan","year":"2019","journal-title":"Cancer Med"},{"issue":"11","key":"2026041408031718200_bib3","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/blood.2020010263","article-title":"Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials","volume":"139","author":"Casulo","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2026041408031718200_bib4","doi-asserted-by":"crossref","first-page":"e1104","DOI":"10.1002\/jha2.1104","article-title":"The prognostic value of POD24 in relapsed\/refractory follicular lymphoma-a SCHOLAR-5 analysis","volume":"6","author":"Limbrick-Oldfield","year":"2025","journal-title":"EJHaem"},{"issue":"1","key":"2026041408031718200_bib5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a singlearm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"2026041408031718200_bib6","first-page":"4407","article-title":"Mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed and\/or refractory follicular lymphoma after \u22652 prior therapies including those with a history of POD24: 4-year follow-up of a pivotal phase \u2161 study","volume":"144","author":"Shadman","year":"2024","journal-title":"EHA"},{"issue":"suppl 1","key":"2026041408031718200_bib7","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1182\/blood-2023-178825","article-title":"Limited duration loncastuximab tesirine with rituximab induces high complete metabolic response rate in high-risk relapsed\/refractory follicular lymphoma\u2014a phase 2 study","volume":"142","author":"Alderuccio","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2026041408031718200_bib8","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41392-024-01798-0","article-title":"Phase II study of novel orally PI3K\u03b1\/\u03b4 inhibitor TQ-B3525 in relapsed and\/or refractory follicular lymphoma","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"2026041408031718200_bib9","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/1078-0432.CCR-22-2939","article-title":"The oral PI3K\u03b4 inhibitor linperlisib for the treatment of relapsed and\/or refractory follicular lymphoma: a phase II, single-arm, open-label clinical trial","volume":"29","author":"Wang","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2026041408031718200_bib10","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol"},{"issue":"33","key":"2026041408031718200_bib11","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1200\/JCO.23.00775","article-title":"ROSEWOOD: a phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma","volume":"41","author":"Zinzani","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"2026041408031718200_bib12","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/01.HS9.0000847492.88194.df","article-title":"P1156: magnify phase 3b study of lenalidomide + rituximab (. R2) followed by maintenance in relapsed\/refractory indolent non-Hodgkin lymphoma: complete induction phase analysis","volume":"6","author":"Lansigan","year":"2022","journal-title":"Hemasphere"},{"key":"2026041408031718200_bib13","doi-asserted-by":"crossref","first-page":"e234_70094","DOI":"10.1002\/hon.70094_234","article-title":"Post hoc analysis of outcomes by POD24 status from the inMIND study of tafasitamab plus lenalidomide and rituximab in relapsed or refractory follicular lymphoma","volume":"43","author":"Sehn","year":"2025","journal-title":"Hematol Oncol"},{"issue":"5","key":"2026041408031718200_bib14","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/bloodadvances.2024014053","article-title":"Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium","volume":"9","author":"Day","year":"2025","journal-title":"Blood Adv"},{"issue":"5","key":"2026041408031718200_bib15","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/ejh.14401","article-title":"Relapsed\/refractory follicular lymphoma: current advances and emerging perspectives","volume":"114","author":"Carid\u00e0","year":"2025","journal-title":"Eur J Haematol"},{"issue":"17","key":"2026041408031718200_bib16","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood.2023021567","article-title":"Durable response after tisagenlecleucel in adults with relapsed\/refractory follicular lymphoma: ELARA trial update","volume":"143","author":"Dreyling","year":"2024","journal-title":"Blood"},{"issue":"8","key":"2026041408031718200_bib17","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat Med"},{"issue":"11","key":"2026041408031718200_bib18","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.annonc.2024.08.2239","article-title":"Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma","volume":"35","author":"Kim","year":"2024","journal-title":"Ann Oncol"},{"issue":"8","key":"2026041408031718200_bib19","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol"},{"key":"2026041408031718200_bib20","article-title":"Randomized phase \u2161 trial comparing lenalidomide\/ obinutuzumab and umbralisib\/obinutuzumab with chemoimmunotherapy in early progressing follicular lymphoma (POD24)","author":"Barr","year":"2025","journal-title":"ASH"},{"issue":"suppl 1","key":"2026041408031718200_bib21","first-page":"3035-2037","article-title":"Tazemetostat in combination with lenalidomide and rituximab in patients with relapsed\/refractory follicular lymphoma: updated phased 1b results of symphony-1 with 22.5 months follow-up","volume":"142","author":"Salles","year":"2023","journal-title":"Blood"},{"key":"2026041408031718200_bib22","doi-asserted-by":"crossref","first-page":"102702","DOI":"10.1016\/j.eclinm.2024.102702","article-title":"Efficacy and safety of MIL62, a novel glycoengineered type \u2161 anti-CD20 monoclonal antibody, combined with lenalidomide in patients with relapsed\/refractory follicular lymphoma or marginal zone lymphoma: a multicentre, single-arm, phase 1b\/2 trial","volume":"73","author":"Shi","year":"2024","journal-title":"eClinicalMedicine"},{"key":"2026041408031718200_bib23","doi-asserted-by":"crossref","first-page":"102747","DOI":"10.1016\/j.eclinm.2024.102747","article-title":"Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1\/2 trial","volume":"74","author":"Gurumurthi","year":"2024","journal-title":"eClinicalMedicine"},{"issue":"8","key":"2026041408031718200_bib24","doi-asserted-by":"crossref","first-page":"e429","DOI":"10.1016\/S2352-3026(19)30089-4","article-title":"Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"2026041408031718200_bib25","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1182\/blood-2024-200262","article-title":"Fixed-duration epcoritamab + R2 drives deep and durable responses in patients with relapsed or refractory follicular lymphoma: 2-year follow-up from arm 2 of the EPCORE NHL-2 trial","volume":"144","author":"Falchi","year":"2024","journal-title":"Blood"},{"issue":"22","key":"2026041408031718200_bib26","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.1182\/bloodadvances.2024013277","article-title":"Magrolimab plus rituximab in relapsed\/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1\/2 trial","volume":"8","author":"Mehta","year":"2024","journal-title":"Blood Adv"},{"issue":"8","key":"2026041408031718200_bib27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41408-021-00539-8","article-title":"Obinutuzumab-atezolizumab- lenalidomide for the treatment of patients with relapsed\/refractory follicular lymphoma: final analysis of a phase Ib\/II trial","volume":"11","author":"Morschhauser","year":"2021","journal-title":"Blood Cancer"},{"issue":"1","key":"2026041408031718200_bib28","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40164-025-00610-1","article-title":"Matching-adjusted indirect comparison of lisocabtagene maraleucel versus epcoritamab in patients with third-line or later relapsed or refractory follicular lymphoma","volume":"14","author":"Dahiya","year":"2025","journal-title":"Exp Hematol Oncol"},{"issue":"suppl 1","key":"2026041408031718200_bib29","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1182\/blood-2023-178786","article-title":"Matching-adjusted indirect comparison (. MAIC) of efficacy and safety of lisocabtagene maraleucel (liso-cel) and mosunetuzumab for the treatment (Tx) of third line or later (3L+) relapsed or refractory (R\/R) follicular lymphoma (FL)","volume":"142","author":"Nastoupil","year":"2023","journal-title":"Blood"},{"issue":"11","key":"2026041408031718200_bib30","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3Kd inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"2026041408031718200_bib31","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/ajh.25711","article-title":"Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study","volume":"95","author":"Dreyling","year":"2020","journal-title":"Am J Hematol"},{"issue":"15","key":"2026041408031718200_bib32","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1200\/JCO.20.03433","article-title":"Umbralisib, a dual PI3Kd\/CK1e inhibitor in patients with relapsed or refractory indolent lymphoma","volume":"39","author":"Fowler","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"2026041408031718200_bib33","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.18.00915","article-title":"DYNAMO: a phase II study of duvelisib (. IPI-145) in patients with refractory indolent non-Hodgkin lymphoma","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"issue":"14","key":"2026041408031718200_bib34","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/7\/2495\/2512620\/blooda_adv-2025-018474-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/7\/2495\/2512620\/blooda_adv-2025-018474-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T12:03:32Z","timestamp":1776168212000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/7\/2495\/566243\/Treatment-and-survival-outcomes-for-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,4,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018474","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,14]]},"published":{"date-parts":[[2026,4,6]]}}}